API
< Back to all clusters
[HEALTH] · India · 2 sources

started · updated

NIPER Raebareli and AstraZeneca partner to expand Indian clinical trials

The National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, and AstraZeneca India have signed a memorandum of understanding to expand clinical trial capacities across India. The partnership aims to decentralize clinical research by developing trained workforces and inspection-ready sites in 25 emerging hubs outside of major metropolitan areas.

The initiative supports the Government of India’s Biopharma SHAKTI program, which seeks to establish 1,000 clinical trial sites nationwide to strengthen the domestic biopharmaceutical ecosystem. Under the agreement, NIPER Raebareli will host a Centre of Excellence to provide structured training and professional certification, while AstraZeneca India will contribute clinical development expertise through workshops, governance support, and readiness assessments.

The Department of Pharmaceuticals will provide strategic guidance to ensure the collaboration aligns with national clinical research priorities. Manoj Joshi, Secretary of the Department of Pharmaceuticals, noted that expanding capabilities beyond metros will help India play a larger role in global clinical trials by tapping into the country’s talent pool.

Entities

AstraZeneca India · Department of Pharmaceuticals · Manoj Joshi · Ministry of Chemicals and Fertilisers · NIPER Raebareli